OKYO
OKYO Pharma Limited
Price Chart
Latest Quote
$1.46
+0.02 (+1.04%)
Current Price
| Previous Close | $1.44 |
| Open | $1.48 |
| Day High | $1.50 |
| Day Low | $1.44 |
| Volume | 5,891 |
Stock Information
| Shares Outstanding | 52.48M |
| Cash Equivalents | $20.59M |
| Net Income | $-8.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $76.36M |
| EPS (TTM) | $-0.24 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $54.98M |
| Income | $-8.95M |
| Book/sh | $0.23 |
| Cash/sh | $0.39 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 2.40 |
| Current Ratio | 2.43 |
Returns & Margins
| ROA | -43.10% |
| ROE | -263.78% |
Ownership
| Insider Ownership | 31.13% |
| Institutional Ownership | 20.10% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.20 |
| P/B | 6.19 |
Analyst Data
| Recommendation | none |
| Target Price | $8.33 |
Technical Indicators
| SMA20 | $1.42 |
| SMA50 | $1.44 |
| SMA200 | $1.64 |
| RSI | 54.21 |
| ATR | 0.0936 |
| Shares Float | 27.94M |
| Short Float | 0.08% |
| Short Ratio | 0.42 |
| Volatility | -0.06 |
| Rel Volume | 0.13 |
Performance History
| Week | +6.20% |
| Month | +6.20% |
| Quarter | -11.28% |
| 6 Months | -7.91% |
| YTD | -34.75% |
| Year | -39.12% |
| 3 Years | -8.49% |
| 10 Years | -59.81% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.46 | 5,891 |
| 2026-10-26 | $1.44 | 16,700 |
| 2026-10-23 | $1.40 | 13,800 |
| 2026-10-22 | $1.47 | 72,500 |
| 2026-10-21 | $1.54 | 241,000 |
| 2026-10-20 | $1.37 | 48,200 |
| 2026-10-19 | $1.40 | 24,100 |
| 2026-10-16 | $1.41 | 25,600 |
| 2026-10-15 | $1.43 | 48,900 |
| 2026-10-14 | $1.41 | 18,500 |
| 2026-10-13 | $1.44 | 20,900 |
| 2026-10-12 | $1.44 | 70,400 |
| 2026-10-09 | $1.42 | 115,500 |
| 2026-10-08 | $1.39 | 27,500 |
| 2026-10-07 | $1.41 | 33,700 |
| 2026-10-06 | $1.46 | 30,400 |
| 2026-10-05 | $1.47 | 11,200 |
| 2026-10-02 | $1.47 | 82,500 |
| 2026-10-01 | $1.34 | 16,900 |
| 2026-09-30 | $1.29 | 6,000 |
| 2026-09-29 | $1.36 | 44,000 |
| 2026-09-28 | $1.37 | 141,700 |
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on OKYO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $473,935 | $870,279 | $1,053,313 | $96,687 |
| Total Expenses | $8,499,553 | $7,091,897 | $15,749,732 | $13,187,200 |
| Net Non Operating Interest Income Expense | $-442,117 | $-878,174 | $-1,053,313 | $-96,687 |
| Total Other Finance Cost | $280 | $13,368 | - | - |
| Interest Expense Non Operating | $473,935 | $870,279 | $1,053,313 | $96,687 |
| Operating Expense | $8,499,553 | $7,091,897 | $15,749,732 | $13,187,200 |
| Other Operating Expenses | $6,690,509 | $4,837,653 | $7,506,161 | $6,849,502 |
| Other Income Expense | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Interest Income | $-442,117 | $-878,174 | $-1,053,313 | $-96,687 |
| Interest Income | $32,098 | $5,473 | $0 | $0 |
| Normalized Income | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Income From Continuing And Discontinued Operation | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Income Common Stockholders | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Income | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Income Including Noncontrolling Interests | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Net Income Continuous Operations | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Pretax Income | $-8,941,670 | $-7,970,071 | $-16,803,045 | $-13,283,887 |
| Interest Income Non Operating | $32,098 | $5,473 | $0 | $0 |
| Operating Income | $-8,499,553 | $-7,091,897 | $-15,749,732 | $-13,187,200 |
| Special Income Charges | - | - | - | $0 |
| Total Operating Income As Reported | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.24 | $-0.12 | $-0.57 | $-0.61 |
| Basic EPS | $-0.24 | $-0.12 | $-0.57 | $-0.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,465,915 | $-7,097,229 | $-15,745,866 | $-13,183,403 |
| Reconciled Depreciation | $1,820 | $2,563 | $3,866 | $3,797 |
| EBITDA (Bullshit earnings) | $-8,465,915 | $-7,097,229 | $-15,745,866 | $-13,183,403 |
| EBIT | $-8,467,735 | $-7,099,792 | $-15,749,732 | $-13,187,200 |
| Diluted Average Shares | $37,357,160 | $39,488,256 | $29,343,727 | $22,257,058 |
| Basic Average Shares | $37,357,160 | $39,488,256 | $29,343,727 | $22,257,058 |
| Diluted NI Availto Com Stockholders | $-8,949,657 | $-4,706,292 | $-16,825,461 | $-13,271,685 |
| Tax Provision | $7,987 | $-3,263,779 | $22,416 | $-12,202 |
| Research And Development | $1,809,044 | $2,254,244 | $8,243,571 | $6,337,698 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Write Off | - | - | - | $0 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
| Selling General And Administration | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-10-17
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Total Assets | $20,976,328 | $3,677,336 | $1,541,264 | $5,203,920 |
| Total Non Current Assets | $6,311 | $2,035 | $3,350 | $7,216 |
| Current Assets | $20,970,017 | $3,675,301 | $1,537,914 | $5,196,704 |
| Prepaid Assets | $205,082 | $225,360 | $130,126 | $171,248 |
| Receivables | $170,667 | $1,889,039 | $580,940 | $980,075 |
| Other Receivables | $4,500 | $4,500 | $5,585 | $340,848 |
| Taxes Receivable | $21,847 | $1,884,539 | $575,355 | $639,227 |
| Cash Cash Equivalents And Short Term Investments | $20,594,268 | $1,560,902 | $826,848 | $4,045,381 |
| Cash And Cash Equivalents | $14,594,268 | $1,560,902 | $826,848 | $4,045,381 |
| Cash Financial | $14,594,268 | $1,560,902 | $826,848 | $4,045,381 |
| Other Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | $2,215,111 |
| Current Debt And Capital Lease Obligation | - | - | - | $2,215,111 |
| Current Debt | - | - | - | $2,215,111 |
| Other Current Borrowings | - | - | - | $2,215,111 |
| Long Term Debt And Capital Lease Obligation | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,641,189 | $9,226,891 | $7,420,846 | $7,257,157 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $8,641,189 | $9,226,891 | $7,420,846 | $7,257,157 |
| Payables And Accrued Expenses | $8,641,189 | $9,226,891 | $7,420,846 | $5,042,046 |
| Payables | $7,137,470 | $8,848,310 | $6,590,671 | $3,166,969 |
| Other Payable | $1,326 | $88,999 | $103,830 | $73,197 |
| Accounts Payable | $7,136,144 | $7,899,986 | $6,128,132 | $2,314,581 |
| Equity | ||||
| Common Stock Equity | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Total Equity Gross Minority Interest | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Stockholders Equity | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Other Equity Interest | $2,877,692 | $2,228,563 | $4,842,358 | $3,711,132 |
| Gains Losses Not Affecting Retained Earnings | $-12,129,559 | $-11,470,420 | $-11,311,447 | $-11,452,542 |
| Retained Earnings | $-151,971,569 | $-143,024,972 | $-142,523,180 | $-125,697,719 |
| Other | ||||
| Ordinary Shares Number | $52,479,257 | $36,020,815 | $33,336,316 | $51,039,764 |
| Share Issued | $52,479,257 | $36,020,815 | $33,336,316 | $51,039,764 |
| Tangible Book Value | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Invested Capital | $12,335,139 | $-5,549,555 | $-5,879,582 | $161,874 |
| Working Capital | $12,328,828 | $-5,551,590 | $-5,882,932 | $-2,060,453 |
| Total Capitalization | $12,335,139 | $-5,549,555 | $-5,879,582 | $-2,053,237 |
| Foreign Currency Translation Adjustments | $-12,129,559 | $-11,470,420 | $-11,311,447 | $-11,452,542 |
| Capital Stock | $173,558,575 | $146,717,274 | $143,112,687 | $131,385,892 |
| Common Stock | $173,558,575 | $146,717,274 | $143,112,687 | $131,385,892 |
| Current Accrued Expenses | $1,503,719 | $378,581 | $830,175 | $1,875,077 |
| Dueto Related Parties Current | $0 | $859,325 | $358,709 | $779,191 |
| Net PPE | $6,311 | $2,035 | $3,350 | $7,216 |
| Accumulated Depreciation | $-8,694 | $-8,465 | $-7,117 | $-8,099 |
| Gross PPE | $15,005 | $10,500 | $10,467 | $15,315 |
| Machinery Furniture Equipment | $15,005 | $10,500 | $10,467 | $15,315 |
| Duefrom Related Parties Current | $144,320 | $0 | - | - |
| Other Short Term Investments | $6,000,000 | $0 | - | - |
| Capital Lease Obligations | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Properties | - | - | - | - |
| Additional Paid In Capital | - | - | - | - |
| Leases | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-10-17
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,941,980 | $-1,812,139 | $-9,490,537 | $-7,701,158 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,935,900 | $-1,810,931 | $-9,490,537 | $-7,695,242 |
| Cash Flow From Continuing Operating Activities | $-5,935,900 | $-1,810,931 | $-9,490,537 | $-7,695,242 |
| Operating Gains Losses | $-703,819 | $-191,262 | $53,764 | $38,780 |
| Investing Activities | ||||
| Capital Expenditure | $-6,080 | $-1,208 | - | $-5,916 |
| Investing Cash Flow | $-6,006,080 | $-1,208 | $0 | $-5,916 |
| Cash Flow From Continuing Investing Activities | $-6,006,080 | $-1,208 | $0 | $-5,916 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $25,023,336 | $1,705,742 | $6,208,508 | $7,323,354 |
| Financing Cash Flow | $25,023,336 | $2,655,742 | $6,208,508 | $9,323,354 |
| Cash Flow From Continuing Financing Activities | $25,023,336 | $2,655,742 | $6,208,508 | $9,323,354 |
| Net Common Stock Issuance | $25,023,336 | $1,705,742 | $6,208,508 | $7,323,354 |
| Common Stock Issuance | $25,023,336 | $1,705,742 | $6,208,508 | $7,323,354 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $0 | $950,000 | $0 | $2,000,000 |
| End Cash Position | $14,594,268 | $1,560,902 | $826,848 | $4,045,381 |
| Beginning Cash Position | $1,560,902 | $826,848 | $4,045,381 | $2,700,724 |
| Effect Of Exchange Rate Changes | $-47,990 | $-109,549 | $63,496 | $-277,539 |
| Changes In Cash | $13,081,356 | $843,603 | $-3,282,029 | $1,622,196 |
| Net Issuance Payments Of Debt | $0 | $950,000 | $0 | $2,000,000 |
| Net Short Term Debt Issuance | $0 | $950,000 | $0 | $2,000,000 |
| Short Term Debt Issuance | $0 | $950,000 | $0 | $2,000,000 |
| Net Investment Purchase And Sale | $-6,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-6,080 | $-1,208 | $0 | $-5,916 |
| Purchase Of PPE | $-6,080 | $-1,208 | $0 | $-5,916 |
| Taxes Refund Paid | $1,953,653 | $1,998,364 | $0 | $199,153 |
| Change In Working Capital | $-630,111 | $1,626,644 | $2,669,464 | $3,945,796 |
| Change In Other Current Assets | $10,914 | $-90,403 | $440,257 | $167,718 |
| Change In Payables And Accrued Expense | $-641,025 | $1,717,047 | $2,229,207 | $3,778,078 |
| Change In Payable | $-641,025 | $1,717,047 | $2,229,207 | $3,778,078 |
| Change In Account Payable | $362,621 | $1,216,431 | $2,799,282 | $2,963,759 |
| Other Non Cash Items | $778,967 | $1,987,842 | $3,464,141 | $114,991 |
| Stock Based Compensation | $1,605,260 | $734,989 | $1,121,273 | $1,286,128 |
| Depreciation Amortization Depletion | $1,820 | $2,563 | $3,866 | $3,797 |
| Depreciation And Amortization | $1,820 | $2,563 | $3,866 | $3,797 |
| Depreciation | $1,820 | $2,563 | $3,866 | $3,797 |
| Gain Loss On Investment Securities | $-3,069 | $-94,284 | $-1,419 | $-12,412 |
| Net Foreign Currency Exchange Gain Loss | $-700,750 | $-96,978 | $55,183 | $51,192 |
| Net Income From Continuing Operations | $-8,941,670 | $-7,970,071 | $-16,803,045 | $-13,283,887 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Change In Receivables | - | - | $0 | $167,718 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Asset Impairment Charge | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-10-17